Symbols / ORGO $2.53 -1.94%

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, VIA Matrix, and SimpliMax are placental tissue grafts used to treat chronic and acute wounds that can be stored at room temperature. The company also provides PuraPly MZ, a micronized version of PuraPly for the management of open wounds in surgical settings; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; and TransCyte, a bioengineered tissue scaffold that promotes burn healing. In addition, it develops ReNu, a cryopreserved suspension, which is in Phase 3 trial, for the management of symptoms associated with knee osteoarthritis; and placental products. The company serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through direct sales representatives and independent agencies. Organogenesis Holdings Inc. is headquartered in Canton, Massachusetts.

Price estimates from analyst targets and simple models.

Latest analyst rating changes

• Organogenesis $ORGO Shares Acquired by First Light Asset Management LLC - MarketBeat Mon, 16 Mar 2026 10
• Organogenesis director Leibowitz buys $13k in ORGO stock - Investing.com hu, 12 Mar 2026 02
• Insider Purchase: Director at $ORGO Buys 10,000 Shares - Quiver Quantitative Wed, 11 Mar 2026 23
• Organogenesis (Nasdaq: ORGO) to file BLA for ReNu knee OA pain by Dec. 2025 - Stock Titan Mon, 15 Dec 2025 08
• Organogenesis Director Makes Bold Insider Move With Fresh Share Purchase - TipRanks hu, 12 Mar 2026 03
• Insider Buying: Organogenesis (NASDAQ:ORGO) Director Buys $13,400.00 in Stock - MarketBeat hu, 12 Mar 2026 11
• Organogenesis (ORGO) VP uses 700 shares to cover tax withholding - Stock Titan ue, 03 Mar 2026 21
• Organogenesis (NASDAQ:ORGO) Director Michael Joseph Driscoll Purchases 10,000 Shares of Stock - MarketBeat Wed, 11 Mar 2026 23
• $ORGO stock is up 30% today. Here's what we see in our data. - Quiver Quantitative Fri, 07 Nov 2025 08
• Wound-care firm Organogenesis hits record sales, warns 2026 drop up to 38% - Stock Titan hu, 26 Feb 2026 21
• Regenerative medicine firm Organogenesis sets Feb. 26 call on 2025 results - Stock Titan hu, 19 Feb 2026 08
• $ORGO stock is up 7% today. Here's what we see in our data. - Quiver Quantitative ue, 16 Dec 2025 08
• Organogenesis (NASDAQ:ORGO) Price Target Cut to $8.00 by Analysts at BTIG Research - MarketBeat Fri, 27 Feb 2026 08
• $ORGO stock is down 10% today. Here's what we see in our data. - Quiver Quantitative Fri, 26 Dec 2025 08
• Biologic treatment for knee arthritis pain begins FDA license bid - Stock Titan ue, 23 Dec 2025 08

• Income Statement
• Balance Sheet
• Cash Flow

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

• 42026-03-11 View
• 42026-03-11 View
• 42026-03-03 View
• 10-K2026-02-26 View
• 8-K2026-02-26 View
• 8-K2026-02-23 View
• 42026-02-20 View
• 42026-02-20 View
• 42026-02-20 View
• 42026-02-20 View
• 42026-02-20 View
• 42026-02-20 View
• 42026-02-20 View
• 42026-02-20 View
• 42026-02-20 View